INTERNATIONAL JOURNAL OF ALTERNATIVE AND CONTEMPORARY THERAPY

# Immunohistochemistry in Tumor Pathology: An Indispensable Tool for The Diagnosis and Classification of Neoplasms

**Rakhimova Sevinchbonu Abdurashidovna**
Clinical resident of the Bukhara Medical Institute. Uzbekistan

**Abstract**.
Immunohistochemistry (IHC) has revolutionized diagnostic surgical pathology, evolving from a research technique to a cornerstone of modern oncologic diagnosis. By visualizing specific antigenic epitopes within the morphological context of tissue architecture, IHC provides critical information that is often unattainable by hematoxylin and eosin (H&E) staining alone. This review synthesizes the pivotal role of IHC in the verification, classification, and prognostic stratification of neoplasms. We discuss its fundamental principles, from antibody selection and antigen retrieval to signal detection and interpretation. The clinical utility of IHC is explored across major tumor types, including carcinomas, sarcomas, lymphomas, and melanocytic lesions, highlighting essential diagnostic, prognostic, and predictive biomarker panels. We address current challenges such as standardization, interpretation variability, and the integration of novel digital and multiplexing technologies. The conclusive evidence underscores IHC as an indispensable, cost-effective method that directly informs therapeutic decisions, enabling personalized cancer care within the framework of precision medicine.
**Keywords**: immunohistochemistry, diagnostic pathology, tumor classification, biomarkers, predictive markers, precision medicine, cancer diagnosis.

## Introduction.

The accurate diagnosis and classification of a neoplasm represent the critical first step in determining patient prognosis and guiding appropriate therapy [1,3]. For decades, histopathological examination of tissue sections stained with hematoxylin and eosin (H&E) has been the gold standard. However, the inherent limitations of morphology—particularly in poorly differentiated tumors, metastatic lesions of unknown primary origin, and small biopsy specimens—can lead to diagnostic uncertainty [2,4,5]. The advent of immunohistochemistry (IHC) in the latter half of the 20th century provided a transformative solution by adding a molecular dimension to morphological analysis.

IHC is a technique that utilizes the specific binding of antibodies to visualize the distribution and localization of target antigens (proteins) within cells and tissues. When applied to tumor pathology, it allows pathologists to identify the cell lineage (epithelial, mesenchymal, lymphoid, melanocytic), determine the site of origin for carcinomas, assess proliferative activity, and detect specific genetic alterations via surrogate protein expression [6]. Beyond diagnosis, IHC is paramount for identifying predictive biomarkers, such as hormone receptors in breast cancer or PD-L1 in various malignancies, which are essential for selecting targeted therapies. This review aims to comprehensively detail the role of IHC as a key verification tool in oncopathology, bridging the gap between classical morphology and molecular diagnostics [8].

Aim of the Study.

The primary aim of this narrative review is to provide a systematic overview of the indispensable role of immunohistochemistry in the diagnosis and classification of neoplasms. We seek to detail its technical principles, outline its application across major tumor categories with specific antibody panels, and evaluate its impact on prognostic and predictive biomarker assessment. Furthermore, we aim to discuss current methodological challenges and future technological directions shaping the field of diagnostic IHC.

## Materials and Methods

This article is a comprehensive narrative review. A systematic literature search was conducted using the PubMed/MEDLINE, Scopus, and Web of Science databases for English-language articles published

between January 2010 and December 2023. Search terms included combinations of: "immunohistochemistry," "IHC," "diagnostic pathology," "tumor classification," "biomarker," "predictive marker," "carcinoma of unknown primary," "lymphoma," "sarcoma," "standardization," "digital pathology," "multiplex IHC." The search focused on high-impact original research articles, consensus guidelines from professional societies (CAP, ASCO), and seminal review articles. Reference lists of key publications were manually screened to identify additional relevant sources. Data were synthesized and organized thematically to address technical aspects, clinical applications by organ system, and emerging trends.

**Results and Discussion**

Technical Foundations and Workflow

A reliable IHC result depends on a meticulously controlled multi-step process: 1) Tissue Preparation: Optimal fixation (typically 10% neutral buffered formalin) and processing are critical to preserve antigenicity. 2) Antigen Retrieval: The application of heat (heat-induced epitope retrieval, HIER) or enzymes is often necessary to unmask epitopes cross-linked by fixation. 3)Primary Antibody Incubation: The specificity and clone of the antibody are paramount. 4) Detection System: Most modern laboratories use polymer-based detection systems with chromogens (eDAB, brown; AEC, red) for visualization. 5) Counterstaining and Interpretation: Slides are counterstained (usually with hematoxylin) and interpreted by a pathologist, assessing the presence, intensity, and subcellular localization (nuclear, cytoplasmic, membranous) of staining. Standardization of each step using automated stainers and validated protocols is essential for reproducible results.

Diagnostic Applications: Determining Lineage and Origin

Carcinoma of Unknown Primary (CUP): IHC is the primary diagnostic tool. A stepwise approach begins with broad-spectrum screening markers: cytokeratins (CK7, CK20) and transcription factors (e.g., TTF-1, NKX3.1, CDX2, PAX8) help narrow down the origin to lung, prostate, gastrointestinal tract, or kidney, among others.

Soft Tissue and Bone Sarcomas: The diagnosis often relies on IHC to confirm mesenchymal lineage (vimentin) and further subclassify. Examples include CD31 and ERG for vascular tumors, desmin and myogenin for rhabdomyosarcoma, and MDM2/CDK4 amplification detection (via IHC) for well-differentiated liposarcoma.

Lymphoid Neoplasms: IHC on tissue sections is fundamental to lymphoma diagnosis. Panels differentiate between B-cell (CD20, PAX5), T-cell (CD3, CD5), and Hodgkin lymphomas (CD15, CD30, PAX5). Specific markers like Cyclin D1 for mantle cell lymphoma or ALK for anaplastic large cell lymphoma are diagnostic.

Melanocytic Tumors: While HMB-45, Melan-A, and S100 are sensitive markers for melanoma, their utility lies in distinguishing melanoma from carcinoma or sarcoma, particularly in amelanotic or metastatic cases.

Prognostic and Predictive Biomarker Assessment

IHC bridges morphology with therapeutic decision-making.

Breast Cancer: Estrogen Receptor (ER) and Progesterone Receptor (PR) status guides endocrine therapy. HER2/neu testing (IHC with reflex in situ hybridization) is mandatory for anti-HER2 targeted therapy eligibility. Ki-67 index provides prognostic information.

Lung Cancer: IHC for PD-L1 expression is a standard predictive biomarker for immune checkpoint inhibitor therapy. ALK, ROS1, and NTRK fusion proteins can also be screened by IHC before confirmatory molecular testing.

Colorectal and Gastric Cancers: Mismatch repair protein deficiency (loss of MLH1, PMS2, MSH2, MSH6) screened by IHC identifies tumors with microsatellite instability, which have prognostic implications and predict response to immunotherapy.

Prostate Cancer: IHC for ERG (a surrogate for TMPRSS2-ERG fusion) and PTEN loss provides prognostic information.

Challenges and Limitations

Despite its power, IHC has limitations. Pre-analytical variables (cold ischemia time, fixation duration) significantly affect staining quality. Interpretation is subjective, leading to inter-observer variability, especially for biomarkers with continuous scores (HER2, PD-L1). Antibody specificity and lack of universal standardization across laboratories can yield discordant results. Tumor heterogeneity may lead to sampling bias, particularly in small biopsies.

Future Directions: Digital and Multiplex IHC

The field is rapidly evolving. Digital Pathology and Image Analysis: Whole-slide imaging coupled with artificial intelligence (AI)-based algorithms offers quantitative, reproducible scoring of biomarkers like Ki-67 or PD-L1, reducing subjectivity. Multiplex Immunohistochemistry/Immunofluorescence (mIHC/mIF): Technologies allowing simultaneous visualization of 6+ markers on a single slide enable deep profiling of the tumor immune microenvironment (characterizing T-cell subsets, macrophage polarization), providing novel prognostic and predictive insights beyond single-plex assays.

Conclusion.

Immunohistochemistry remains an irreplaceable and pivotal technique in the diagnostic pathology of neoplasms. It successfully merges morphological assessment with molecular phenotyping, resolving diagnostic dilemmas, refining tumor classification, and unlocking essential prognostic and predictive information. As the cornerstone of companion diagnostics, IHC directly enables personalized oncology by identifying therapeutic targets. While challenges in standardization persist, ongoing technological advancements in automation, digital quantification, and multiplexing are set to enhance the precision, reproducibility, and informational yield of IHC. Its integration with next-generation sequencing and other omics platforms will further solidify its role as a fundamental pillar in the comprehensive, multidisciplinary approach to cancer diagnosis and treatment.

**References**

1. Taylor CR, Levenson RM. Quantification of immunohistochemistry--issues concerning methods, utility and semiquantitative assessment II. Histopathology. 2006 Oct;49(4):411-24. doi: 10.1111/j.1365-2559.2006.02513.x.

2. Dabbs DJ. Diagnostic Immunohistochemistry: Theranostic and Genomic Applications. 6th ed. Philadelphia, PA: Elsevier; 2020.

3. Hodi FS, Ballinger M, Lyons B, et al. Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy. J Clin Oncol. 2018 Mar 10;36(8):850-858. doi: 10.1200/JCO.2017.75.1644.

4. Lim HJ, Lee MH. Principles of Immunohistochemistry. In: Lee H, Kim H, editors. Cancer Biomarkers. Clinical Aspects and Laboratory Determination. Singapore: Springer; 2021. p. 25-40.

5. Tan WW, Li H, Chung I. Antibody Validation for Protein Expression on Tissue Sections. J Histochem Cytochem. 2020 May;68(5):325-333. doi: 10.1369/0022155420920866.

6. Weissferdt A, Kalhor N, Bishop JA, et al. Immunohistochemistry in the Diagnosis of Thoracic Tumors: A Practical Approach. Arch Pathol Lab Med. 2020 Sep 1;144(9):1015-1031. doi: 10.5858/arpa.2020-0072-RA.

7. Wolff AC, Hammond MEH, Allison KH, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. Arch Pathol Lab Med. 2018 Nov;142(11):1364-1382. doi: 10.5858/arpa.2018-0902-SA.

8. Taube JM, Akturk G, Angelo M, et al. The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation. J Immunother Cancer. 2020 May;8(1):e000155. doi: 10.1136/jitc-2019-000155.